白云山 2024 年年度股东大会 广州白云山医药集团股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 3 日 第 1 页 共 48 页 白云山 2024 年年度股东大会 | 目 | 录 | | --- | --- | | 一、会议须知…………………………………………………………3 | | | 二、会议议程…………………………………………………………5 | | | 三、会议议案…………………………………………………………7 | | 第 2 页 共 48 页 白云山 2024 年年度股东大会 广州白云山医药集团股份有限公司 2024 年年度股东大会会议须知 为了维护广州白云山医药集团股份有限公司（以下简称"广药白 云山"、"本公司"、"公司"）全体股东的合法权益，确保本公司 2024 年年度股东大会（以下简称"本次股东大会"或"年度股东大会"） 正常秩序和议事效率，保证本次股东大会的顺利进行，依据有关法律 法规、本公司《广州白云山医药集团股份有限公司章程》（以下简称 "《公司章程》"）及《广州白云山医药集团股份有限公司股东大会 议事规则》（以下简称"《股东大会议事规则》"）的有关规定，特 制订 ...

证券代码：600332 证券简称：白云山 公告编号：2025—042 广州白云山医药集团股份有限公司 关于子公司通过高新技术企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广西白云山盈康药业有限公司（以下简称"广西盈康"）已通 过高新技术企业重新认定，并收到由广西壮族自治区科学技术厅、广 西壮族自治区财政厅、国家税务总局广西壮族自治区税务局联合颁发 的《高新技术企业证书》，证书有关信息具体如下： 企业名称：广西白云山盈康药业有限公司 证书编号：GR202445000589 发证日期：2024年12月7日 有效期：三年 广西盈康通过高新技术企业认定后，根据国家的相关规定，自获 得高新技术企业认定后连续三年内（2024年、2025年和2026年）可享 受国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业 所得税。2024年本公司已按照15%的所得税税率计缴该公司所得税。 本次广西盈康获得《高新技术企业证书》不会对本公司当期经营业绩 产生重大 ...

Group 1 - Recent demand for home testing and antiviral medications has surged, with COVID-19 antigen search demand in Beijing, Shanghai, Guangzhou, and Shenzhen increasing by 3-5 times compared to the previous week [1] - Home testing service orders on Meituan have increased by 30% year-on-year over the past four days, while orders for COVID-related antiviral medications have more than doubled compared to the previous week [1] - Meituan Health has launched a special public welfare program in collaboration with Wanfang Biological and medical device merchants, allowing users to purchase COVID-19 antigen test kits for just one cent, targeting high-demand cities [1] Group 2 - Guangzhou Pharmaceutical Group's subsidiary, Baiyunshan and Huang Zhong Medicine, reports that current production capacity can meet market demand for antiviral drugs [2] - The company has collaborated with academic experts for over ten years, discovering that Banlangen has multi-target antiviral properties and can help regulate excessive immune responses [2] - The formulation of Kouyanqing granules, which includes various traditional Chinese medicinal ingredients, is effective in treating oral and throat diseases, potentially alleviating symptoms of pharyngitis [2]

Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].

Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

药品行业趋势快报 2025年1-4月 数据来源 p 硬广统计平台：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） p 综艺统计平台：电综：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） 网综-爱优腾芒等主流视频平台 p 网剧统计平台：爱奇艺、优酷、腾讯视频、芒果TV等四大平台，剧集播出首轮品牌监测 p 网剧合作类型：剧内植入-影视剧剧内品牌植入，指口播、片尾鸣谢、置景道具、互动道具等资源；平台自招商：指 标板、角标、预告/回顾、创可贴、创意中插、片尾彩蛋、明星播报、压屏条、内容提示等资源 p 报告中客户数量均按照厂商数统计；报告中去除非商业合作客户：音乐、视频、场地合作、新浪等非商业客户 p 报告统计周期：2025年1月-4月 硬广-药品客户在央视系列频道投放数量及时长均领先，投放时长占比超58% 数据来源：击壤科技 2025年1-4月 央卫视49频道硬广 • 截至25年4月，药品硬广客户数（厂商数）共计191个，投放时长总计3,214,104 秒；从媒体层级看，多投放央视系列频道，央视频道投放时长占比高达58.1 ...

Core Viewpoint - The article discusses the serious disciplinary violations and illegal activities of Li Chuyuan, the former Party Secretary and Chairman of Guangzhou Pharmaceutical Group Co., Ltd., leading to his expulsion from the Party and removal from public office [2][3]. Group 1: Disciplinary Actions - Li Chuyuan was expelled from the Party and removed from public office due to severe violations of political, organizational, and ethical disciplines, constituting serious job-related crimes [3]. - His illegal activities included engaging in superstitious practices, misuse of public resources, and accepting bribes, which were investigated by the Guangdong Provincial Commission for Discipline Inspection [2][3]. Group 2: Company Background - Guangzhou Pharmaceutical Group Co., Ltd. is a state-owned enterprise authorized by the Guangzhou government, involved in the research, production, and sales of traditional Chinese medicine, chemical drugs, and health products [5]. - The company operates several well-known brands, including "Wanglaoji" and "Baiyunshan," with significant brand values of 108 billion and 28.3 billion respectively [5]. Group 3: Li Chuyuan's Career - Li Chuyuan has held various positions within the company since 1988, eventually becoming the Chairman in 2013, and has been recognized with multiple awards and honors throughout his career [6][7]. - His public statements during events, particularly regarding the efficacy of the company's products, have sparked controversy and debate [7].

Group 1 - The core viewpoint of the articles highlights the successful establishment of the Gansu Guangyao Baiyunshan Traditional Chinese Medicine Technology Co., Ltd. in Longxi, showcasing effective collaboration between government and enterprises to boost local industry [1][2] - The project is expected to generate significant revenue, with sales projected to exceed 500 million yuan in 2024 and reach 200 million yuan by 2025, indicating strong market demand for its products [1] - Longxi County has implemented a "three-pronged" service mechanism to facilitate investment projects, resulting in 158 projects with a total investment of 28.43 billion yuan over the past three years [2] Group 2 - Longxi County, known for its rich history in traditional Chinese medicine, has faced challenges due to a lack of deep processing enterprises, which has hindered the development of its medicinal industry [2] - The collaboration between Guangyao Group and Longxi County is seen as a turning point, injecting capital and restructuring the industrial ecosystem, thus addressing the previous bottlenecks in the local industry [2] - The county has adopted customized policies to support enterprises at various growth stages, securing over 34.4 million yuan in technology funding from provincial and municipal sources in the past three years [2]

Group 1 - The establishment of the headquarters of Wanglaoji Health Company on Guangzhou International Bio Island marks a strategic upgrade towards a technology-driven health enterprise for the Guangzhou Pharmaceutical Group [1][3] - Guangzhou International Bio Island has gathered over 500 top research institutions and companies, positioning itself as a "golden track" for the health industry and a test of competitiveness [3] - The relocation of the headquarters is not just a spatial change but aims to leverage the "Lighthouse Effect" of Bio Island to accelerate scientific research innovation and digital transformation [3] Group 2 - Wanglaoji signed a strategic cooperation agreement with South Korea's Nongshim Group, focusing on channel sharing, brand promotion, and joint product and technology development [4] - This partnership is the first international collaboration project following Wanglaoji's move to the Bio Island headquarters, highlighting the dual strategy of technology enhancement and globalization [4] - The collaboration aims to enhance product capabilities through Bio Island's research resources while leveraging Nongshim's international market presence to facilitate global competition for Chinese health beverages [4]

Core Viewpoint - The high-quality performance of the Gaozhou Puppet Show, a national intangible cultural heritage, attracted a large audience at the event held in Guangzhou's Baiyun Mountain, showcasing the cultural richness and innovative spirit of the art form [1][5][19]. Group 1: Event Overview - On May 1, the Gaozhou Puppet Show performed "Xian Tai Lian Bing" at Baiyun Mountain, drawing significant attention from citizens and tourists [2][8]. - The event featured various performances, including "Nezha," "Retro Disco," and "Tang Gu La Feng Bao," which combined traditional puppet techniques with contemporary themes to engage younger audiences [16][18]. Group 2: Cultural Significance - Gaozhou Puppet Show, also known as "Gui Zi Xi," was recognized as a national intangible cultural heritage in 2006, highlighting its historical and cultural importance [20][21]. - The show has a strong local support system, with 2 national-level inheritors, 4 city-level, and 5 county-level inheritors, along with a puppet association comprising over 500 members and 132 puppet troupes [21][22]. Group 3: Audience Engagement - The audience actively participated in the event, capturing performances on their phones and engaging in interactive games, which contributed to the lively atmosphere [4][29]. - The event also included a promotional segment for Gaozhou's agricultural and cultural tourism products, with over 40 enterprises showcasing more than 100 products [31][32]. Group 4: Agricultural Promotion - Gaozhou, known as the "Hometown of Lychee," produces over 500,000 tons of lychee annually, accounting for one-fourth of China's total lychee production [36]. - The city launched customized lychee activities targeting various groups, enhancing community engagement and promoting local agricultural products [38][43].